To include your compound in the COVID-19 Resource Center, submit it here.

Product Development
I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five ...

Emerging Company Profile
Nura reveals neuroprotective lead target, first part of its neurology one-two punch

Nura Bio emerged from stealth last week with a $73 million series A and strategy to tackle neurological disorders based on two prevailing theories -- increasing neuroprotection and ...

Data Bytes: led by ex-U.S. biopharmas, July follow-ons bring in $5.8B

July saw $5.8 billion in follow-on capital raised across 36 biopharma offerings, bringing

Read the full 136 ...

Management Tracks
CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

COO Franz-Werner Haas will become CureVac AG’s permanent CEO, the mRNA vaccines company’s third this year. He has filled the role on an interim basis since ...

BioCentury ISSN 1097-7201